Literature DB >> 15644461

Effects of chronic inhibition of inducible nitric oxide synthase in hyperthyroid rats.

Isabel Rodríguez-Gómez1, Rosemary Wangensteen, Juan Manuel Moreno, Virginia Chamorro, Antonio Osuna, Félix Vargas.   

Abstract

We hypothesized that nitric oxide generated by inducible nitric oxide synthase (iNOS) may contribute to the homeostatic role of this agent in hyperthyroidism and may, therefore, participate in long-term control of blood pressure (BP). The effects of chronic iNOS inhibition by oral aminoguanidine (AG) administration on BP and morphological and renal variables in hyperthyroid rats were analyzed. The following four groups (n = 8 each) of male Wistar rats were used: control group and groups treated with AG (50 mg.kg(-1).day(-1), via drinking water), thyroxine (T4, 50 microg.rat(-1).day(-1)), or AG + T4. All treatments were maintained for 3 wk. Tail systolic BP and heart rate (HR) were recorded weekly. Finally, we measured BP (mmHg) and HR in conscious rats and morphological, plasma, and renal variables. T(4) administration produced a small BP (125 +/- 2, P < 0.05) increase vs. control (115 +/- 2) rats. AG administration to normal rats did not modify BP (109 +/- 3) or any other hemodynamic variable. However, coadministration of T4 and AG produced a marked increase in BP (140 +/- 3, P < 0.01 vs. T4). Pulse pressure and HR were increased in both T4- and T4 + AG -treated groups without differences between them. Plasma NOx (micromol/l) were increased in the T4 group (10.02 +/- 0.15, P < 0.05 vs. controls 6.1 +/- 0.10), and AG reduced this variable in T4-treated rats (6.81 +/- 0.14, P < 0.05 vs. T4) but not in normal rats (5.78 +/- 0.20). Renal and ventricular hypertrophy and proteinuria of hyperthyroid rats were unaffected by AG treatment. In conclusion, the results of the present paper indicate that iNOS activity may counterbalance the prohypertensive effects of T4.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15644461     DOI: 10.1152/ajpendo.00279.2004

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  6 in total

1.  Differential involvement of various sources of reactive oxygen species in thyroxin-induced hemodynamic changes and contractile dysfunction of the heart and diaphragm muscles.

Authors:  Mohammad T Elnakish; Eric J Schultz; Rachel L Gearinger; Nancy S Saad; Neha Rastogi; Amany A E Ahmed; Peter J Mohler; Paul M L Janssen
Journal:  Free Radic Biol Med       Date:  2015-03-17       Impact factor: 7.376

2.  The role of allopurinol on oxidative stress in experimental hyperthyroidism.

Authors:  O Makay; C Yenisey; G Icoz; N Genc Simsek; G Ozgen; M Akyildiz; E Yetkin
Journal:  J Endocrinol Invest       Date:  2009-09       Impact factor: 4.256

3.  L-Arginine metabolism in cardiovascular and renal tissue from hyper- and hypothyroid rats.

Authors:  Isabel Rodríguez-Gómez; Juan N Moliz; Andrés Quesada; Sebastian Montoro-Molina; Pablo Vargas-Tendero; Antonio Osuna; Rosemary Wangensteen; Félix Vargas
Journal:  Exp Biol Med (Maywood)       Date:  2015-12-15

Review 4.  Role of Oxidative Stress in Thyroid Hormone-Induced Cardiomyocyte Hypertrophy and Associated Cardiac Dysfunction: An Undisclosed Story.

Authors:  Mohammad T Elnakish; Amany A E Ahmed; Peter J Mohler; Paul M L Janssen
Journal:  Oxid Med Cell Longev       Date:  2015-06-04       Impact factor: 6.543

5.  The effects of ischemic postconditioning on myocardial function and nitric oxide metabolites following ischemia-reperfusion in hyperthyroid rats.

Authors:  Jalal Zaman; Sajjad Jeddi; Asghar Ghasemi
Journal:  Korean J Physiol Pharmacol       Date:  2014-12-30       Impact factor: 2.016

6.  Recovery following Thyroxine Treatment Withdrawal, but Not Propylthiouracil, Averts In Vivo and Ex Vivo Thyroxine-Provoked Cardiac Complications in Adult FVB/N Mice.

Authors:  Nancy S Saad; Steven J Repas; Kyle Floyd; Paul M L Janssen; Mohammad T Elnakish
Journal:  Biomed Res Int       Date:  2017-07-16       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.